Investor relations UKGSK plc79 New Oxford StreetLondonWC1A 1DG Tel: +44 (0)20 8047 5000 Email Investor relations Email Corporate access Constantin Fest, SVP, Head of IR (London) +44 7831 826525 Annabel Gleeson, VP, IR (London) +44 7901 101944 Frannie DeFranco, IR Director (Philadelphi...
Investors UK Investor relations US Investor relations Shareholder FAQs Media Global media contacts US media contacts Market websites for local media contacts Careers Search jobs Work in GSK AI Our global and regional hubsPartnerships and suppliers Partnerships information Collaboration submission portal...
GSK PLC Faces Class Action Lawsuit Over Alleged Securities Fraud Apr. 1, 2025 at 8:03 a.m. ET on GuruFocus.com Barclays Keeps Their Hold Rating on GlaxoSmithKline (GSK) Mar. 31, 2025 at 2:36 a.m. ET on TipRanks.com GSK pushes UK government to give more access to health data...
Wave’s Duchenne Exon-Skipper Reverses Muscle Damage in Mid-Stage Trial March 26, 2025 · 3 min read · Heather McKenzie FDA GSK Wins FDA Nod for First Oral UTI Antibiotic in Almost 30 Years March 26, 2025 · 2 min read · Tristan Manalac ...
Investor Relations: Nick Stone +44 (0) 7717 618834 (London) James Dodwell +44 (0) 20 8047 2406 (London) Mick Readey +44 (0) 7990 339653 (London) Josh Williams +44 (0) 7385 415719 (London) Camilla Campbell +44 (0) 7803...
HS-20093 has shown promising initial clinical activity in lung cancer with potential to address unmet medical need in broader solid tumour indications (20 December 2023, London UK)GSK plc (LSE/NYSE: GSK) and Hansoh Pharma (HKEX: 03692), a Chinese biopharmaceutical company committed to discovering...
formulary coverage expected to improve outlook 10% NRx growth (LABA / ICS) Medicare Part D coverage 5% Jan Jan Market 2014 2015 0% Advair + Breo Breo 2% 74% -5% -10% * Data presented for Advair removed due to restatement, please call Advair GSK Investor Relations if you have questions....
See the winners Contact salesStart free trial LearnSimilarweb AcademyHelp CenterDevelopers Center ExploreBlogCustomer StoriesReports & InsightsWebinars CompanyAbout UsOur DataInvestor Relations LatestDigital 100 is live!From apparel to personal finance to gaming, and much more, explore the winners in our...
GSK’s response to an Investor Forum letter, regarding GSK’s redefined operating model post-Demerger. GSK’s response to an Investor Forum letter (PDF - 232.4KB) 21 October 2022 Investor science event: Getting ahead of respiratory syncytial virus in older adults After presenting the positive ...
We have engaged Computershare Investor Services PLC as our ordinary share registrar. Computershare Investor Services PLC and other Computershare Group entities (“Computershare”) maintain the GSK shareholder register and processes shareholders’ personal information on our behalf. What we do with your ...